• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Nevro raising more than $300m through public offering, convertible senior notes

Nevro raising more than $300m through public offering, convertible senior notes

April 2, 2020 By Sean Whooley

NevroNevro (NYSE:NVRO) announced today that it priced concurrent underwritten public offerings of more than 1.6 million common stock shares, as well as convertible senior notes, to raise more than $300 million.

The offering of 1,625,000 total shares of common stock at a price of $84.00 per share is slated to bring gross proceeds of approximately $136.5 million before the necessary deductions. For the concurrent $165 million senior notes offering, the company is including 2.75% convertible senior notes due in 2025.

Redwood City, Calif.-based Nevro granted the underwriters of the offerings a 30-day option to purchase an additonal 243,750 shares of common stock at the public offering price and $24.75 million aggregate amounts in notes. All shares of common stock are set to be offered by the company itself, with the offerings expected to close on April 6.

Interest on the senior notes will run at a rate of 2.75% per year, payable semi-annually in arrears on April 1 and Oct. 1 of each year, beginning on Oct. 1, 2020. The notes are set to mature on April 1, 2025, unless earlier repurchased or converted. Nevro is not able to redeem the notes and no sinking fund is provided.

In connection with the pricing, Nevro entered into privately negotiated convertible note hedge transactions with one or more of the underwriters and/or their affiliates and/or other institutions. The transactions are set to cover the number of shares of Nevro’s common stock that will initially underlie the notes and are expected to reduce the potential equity dilution and/or offset cash payments in excess of the principal amount due.

The neurostimulation company also entered into privately negotiated warrant transactions at a higher strike price, initially set at $147 per share, which represents a premium of about 75% over the public offering price.

According to a news release, Nevro plans to use a portion of the proceeds from the offerings to pay the cost of the convertible note hedge transactions, with the remainder earmarked for general corporate purposes, including repaying its 1.75% convertible senior notes due in 2021 at maturity.

Filed Under: Business/Financial News, Featured, Funding Roundup, Neurological, Neuromodulation/Neurostimulation Tagged With: Nevro Corp.

More recent news

  • Penumbra completes enrollment in pulmonary embolism trial
  • Zoll opens new facility in Rhode Island
  • FDA expands clearance for Inquis Medical’s Aventus thrombectomy system
  • SS Innovations completes first robotic cardiac surgery in the Americas
  • GI Windows wins FDA nod for magnet tech

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy